Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Agomelatine for the treatment of major depressive disorder.

Carney RM, Shelton RC.

Expert Opin Pharmacother. 2011 Oct;12(15):2411-9. doi: 10.1517/14656566.2011.607812. Review.

PMID:
21916789
2.

Agomelatine targets a range of major depressive disorder symptoms.

Dubocovich ML.

Curr Opin Investig Drugs. 2006 Jul;7(7):670-80. Review.

PMID:
16869122
3.

The mechanism, efficacy, and tolerability profile of agomelatine.

MacIsaac SE, Carvalho AF, Cha DS, Mansur RB, McIntyre RS.

Expert Opin Pharmacother. 2014 Feb;15(2):259-74. doi: 10.1517/14656566.2014.862233. Epub 2013 Dec 16. Review.

PMID:
24328686
4.

Agomelatine: AGO 178, AGO178, S 20098.

[No authors listed]

Drugs R D. 2008;9(3):177-83.

PMID:
18457470
5.

Agomelatine, a melatonin agonist with antidepressant properties.

Dubovsky SL, Warren C.

Expert Opin Investig Drugs. 2009 Oct;18(10):1533-40. doi: 10.1517/13543780903292634. Review.

PMID:
19758108
6.

[Agomelatine].

Tessmer M.

Med Monatsschr Pharm. 2009 Aug;32(8):282-8. Review. German.

PMID:
19777735
7.

Agomelatine for major depressive episodes.

[No authors listed]

Drug Ther Bull. 2010 Aug;48(8):93-6. doi: 10.1136/dtb.2010.08.0043. Review.

PMID:
20685900
8.

[Agomelatine: the first "melatoninergic" antidepressant].

Bánki MC.

Neuropsychopharmacol Hung. 2006 Oct;8(3):105-12. Review. Hungarian.

PMID:
17211046
9.

Agomelatine treatment of major depressive disorder.

Dolder CR, Nelson M, Snider M.

Ann Pharmacother. 2008 Dec;42(12):1822-31. doi: 10.1345/aph.1L296. Epub 2008 Nov 25. Review.

PMID:
19033480
10.

Agomelatine in depression.

Smeraldi E, Delmonte D.

Expert Opin Drug Saf. 2013 Nov;12(6):873-80. doi: 10.1517/14740338.2013.828690. Epub 2013 Sep 16. Review.

PMID:
24033095
11.

The use of antidepressants in clinical practice: focus on agomelatine.

McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S.

Hum Psychopharmacol. 2010 Mar;25(2):95-102. doi: 10.1002/hup.1094. Review.

PMID:
20196187
12.

The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.

De Berardis D, Di Iorio G, Acciavatti T, Conti C, Serroni N, Olivieri L, Cavuto M, Martinotti G, Janiri L, Moschetta FS, Conti P, Di Giannantonio M.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):119-32. Review.

PMID:
20874703
13.

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.

Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V.

Int Clin Psychopharmacol. 2010 Nov;25(6):305-14. doi: 10.1097/YIC.0b013e32833a86aa.

PMID:
20856123
14.

Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.

de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ.

Nat Rev Drug Discov. 2010 Aug;9(8):628-42. doi: 10.1038/nrd3140. Epub 2010 Jun 25. Review. Erratum in: Nat Rev Drug Discov. 2010 Sep;9(9):743.

PMID:
20577266
15.
16.

Agomelatine: new drug. Adverse effects and no proven efficacy.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):241-5.

PMID:
20020562
17.

Treating each and every depressed patient.

Kennedy SH.

J Psychopharmacol. 2008 Sep;22(7 Suppl):19-23. doi: 10.1177/0269881108093270. Review.

PMID:
18753279
18.

Agomelatine in treating generalized anxiety disorder.

Demyttenaere K.

Expert Opin Investig Drugs. 2014 Jun;23(6):857-64. doi: 10.1517/13543784.2014.911840. Epub 2014 Apr 28. Review.

PMID:
24766542
19.

Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.

Olié JP, Kasper S.

Int J Neuropsychopharmacol. 2007 Oct;10(5):661-73. Epub 2007 May 4.

PMID:
17477888
20.

Role of melatonin in mood disorders and the antidepressant effects of agomelatine.

Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A.

Expert Opin Investig Drugs. 2012 Oct;21(10):1503-22. Epub 2012 Aug 9. Review.

PMID:
22876742

Supplemental Content

Support Center